Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04759183
Other study ID # STUDY00022194
Secondary ID NCI-2021-00794ST
Status Completed
Phase N/A
First received
Last updated
Start date March 5, 2021
Est. completion date August 25, 2022

Study information

Verified date September 2022
Source OHSU Knight Cancer Institute
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This trial studies the impact of virtual reality experiences on anxiety before surgery and pain after surgery. The goal of this study is to examine how different virtual reality experiences may help reduce anxiety and improve pain control, which may help reduce the need for medications such as opioids.


Description:

PRIMARY OBJECTIVE: I. To measure the impact of a gaming virtual reality (VR) experience compared to a mindfulness VR experience on preoperative anxiety and postoperative pain. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I: Patients participate in a VR intervention (Angry Birds) over 15 minutes before standard of care surgery and then participate in a VR intervention (TRIPP) over 15 minutes after surgery. ARM II: Patients participate in a VR intervention (TRIPP) over 15 minutes before standard of care surgery and then participate in a VR intervention (Angry Birds) over 15 minutes after surgery.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date August 25, 2022
Est. primary completion date April 11, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 89 Years
Eligibility Inclusion Criteria: - Adults (18 years or older and younger than 89) - Able to consent - English-speaking Exclusion Criteria: - Non-English speaking patients because the VR content is only available in English - Have symptoms concerning for an active respiratory infection or are on contact or isolation precautions - Any active eye discharge - A history of seizure, epilepsy, or hypersensitivity to flashing light - Have a history of motion sickness or vertigo - Have active nausea or vomiting - Psychiatric conditions that may interfere with the ability to successfully participate in the study - Have cardiac pacemakers - Require hearing aids at all times that cannot be removed - Have defibrillators - Have wound dressings on the head or neck that prevent comfortable use of the VR headset

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Survey Administration
Ancillary studies
Procedure:
Virtual Reality Game
Participate in VR Game "Angry Birds"
Virtual Reality Meditation
Participate in VR Meditation "TRIPP"

Locations

Country Name City State
United States OHSU Knight Cancer Institute Portland Oregon

Sponsors (2)

Lead Sponsor Collaborator
OHSU Knight Cancer Institute Oregon Health and Science University

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in preoperative anxiety scores Assessed by visual analogue scale (VAS) from 0-100mm. Baseline up to pre surgery (estimated 1 day)
Primary Change in postoperative pain scores Assessed by VAS scale from 0-100mm. Baseline after surgery up to study completion (estimated 1 day)
Secondary Change in blood pressure mmHg immediately before intervention, and then immediately after intervention (estimated 1 day)
Secondary Patient enjoyment of each VR experience Likert scale (1-5). 1 represents the lowest score, and 5 represents the highest. Up to study completion (estimated 1 day)
Secondary Change in heart rate beats per minute (bpm) immediately before intervention, and then immediately after intervention (estimated 1 day)
Secondary Patient desire to use VR more in their healthcare Likert scale (1-5). 1 represents the lowest score, and 5 represents the highest. Up to study completion (estimated 1 day)
See also
  Status Clinical Trial Phase
Recruiting NCT06030427 - Virtual Mindfulness and Weight Management to Mitigate Risk of Relapse and Improve Wellbeing in Cancer Survivors N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT05660421 - Itacitinib for the Treatment Steroid Refractory Immune Related Adverse Events Arising From Immune Checkpoint Inhibitors Phase 2
Suspended NCT04060849 - Nozin in Preventing Respiratory Viral Infections in Patients Undergoing Stem Cell Transplant, PREV-NOSE STUDY Phase 1
Recruiting NCT06192875 - A Novel Molecular Approach to Blood DNA Screening for Cancer: Specificity Assessment (The NOMAD Study)
Completed NCT04122118 - Pharmacist-led Transitions of Care in the Outpatient Oncology Infusion Center for Patients With Solid Tumor N/A
Active, not recruiting NCT04940299 - Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma Phase 2
Active, not recruiting NCT03168737 - 18F-Fluoroazomycin Arabinoside PET-CT in Diagnosing Solid Tumors in Patients Phase 1
Active, not recruiting NCT06062901 - An Educational Intervention on Provider Knowledge for the Support of Cancer Survivors N/A
Active, not recruiting NCT02444741 - Pembrolizumab and Stereotactic Body Radiation Therapy or Non-Stereotactic Wide-Field Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer Phase 1/Phase 2
Terminated NCT04081298 - eHealth Diet and Physical Activity Program for the Improvement of Health in Rural Latino Cancer Survivors N/A
Active, not recruiting NCT04555837 - Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer Phase 1/Phase 2
Completed NCT04983901 - PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN Phase 2
Active, not recruiting NCT04602026 - The RIOT Trial: Re-Defining Frailty and Improving Outcomes With Prehabilitation for Pancreatic, Liver, or Gastric Cancer N/A
Recruiting NCT04871542 - Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
Active, not recruiting NCT04592250 - Financial Toxicity in Cancer Patients
Recruiting NCT05112614 - Role of Gut Microbiome in Cancer Therapy
Active, not recruiting NCT04296305 - Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain Phase 4
Recruiting NCT05873608 - Communication Issues in Patient and Provider Discussions of Immunotherapy N/A
Recruiting NCT02464696 - Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure N/A